COVID-19 and HealthTech Innovation: An Interview with Scott Gottlieb

article image

Scott Gottlieb, MD, former FDA commissioner and special partner at NEA, shares his perspective on the challenges of regulating technologies during COVD-19 and what to expect going forward. From the Innovator’s Workbench Speaker’s Series hosted by the Byers Center for Biodesign at Stanford University, January 21, 2021.

At this year’s first Innovator’s Workbench session from Stanford’s Biodesign program, former FDA Commission Scott Gottlieb, MD, talks about his career as the medtech industry’s top regulator and offers some thoughts on how the COVID pandemic has affected the medical device industry.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: